Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
09:03a ALLIANCE FIBER OPTIC PRODUCTS : Submission of Matters to a Vote of Security Holders (form 8-K)
09:03a GAP : Marissa Webb's First Designs for Banana Republic Aren't Hitting the Mark With Shoppers
09:03a URANERZ ENERGY : ; Consideration of Approval of Transfer of License
09:03a MARATHON PETROLEUM : Notice of Lodging of Proposed Consent Decree Under the Clean Air Act
09:03a EMPIRE DISTRICT ELECTRIC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
09:03a BMO Funds, Inc. and BMO Asset Management Corp.; Notice of Application
09:03a Cushing® Renaissance Fund Announces Quarterly Distribution
09:03a A.M. BEST : Affirms Ratings of Amlin AG, Lloyd’s Syndicate 2001 and Amlin plc
09:02a MEIHUA : Xanthan Gum From the People's Republic of China: Final Results of 2013 Antidumping Duty New Shipper Review
09:02a DIRECTOR DEALINGS SUMMARY : Glencore Non-Executive Cuts Stake
Latest news
Advertisement
Hot News 
TYRATECH : best of the rest
OUTSOURCERY : Hybrid cloud: the best of both worlds
JOYOU : Insolvency application will be filed/Revocation of audit opinions for the fiscal year 2014/ Change to management board/ Examination of legal actions against JiansheCaiand Jilin Cai
AMUR MINERALS : Kun-Manie Production Licence Awarded
COATS : Results of Meeting
Most Read News
05/21 McDonald's CEO gets grilled at first annual meeting
05/21 HSBC wins reversal of $2.46 billion Household judgment
05/21 HP forecasts split-related costs below expectations
05/21 CHARTER IN TALKS WITH TIME WARNER CABLE OVER BID LIKELY ABOVE $170 PER SHARE : Wsj
05:16a Nationwide predicts higher house prices as profits rise
Most recommended articles
08:57a British-based banks planning for EU 'no' stymied by lack of European office space
08:55aDJAnn Struggles with Weak Traffic
08:55aDJConsumer Prices Up 0.1% in April
08:47aDJDollar Strengthens Against Euro, Yen On U.S. CPI Data
08:46aDJCanada Retail Sales Climbs 0.7% in March
Dynamic quotes  
ON
| OFF